RSV Vaccine 90% Effective in High-Risk Adults, Real-World Study Shows
The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against hospitalizations or emergency department (ED) visits associated with respiratory syncytial virus (RSV), according to recent real-world data presented at the IDWeek annual meeting in Los Angeles.
Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial ...
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
The maternal RSV vaccine is currently only available in Australia to women in the late stages of pregnancy and costs up to 350 AUD (230.3 USD).
Doctors detail what we learned after the first season following the approval of RSV vaccines. The vaccine effectively prevented severe illness in older, but only 24 percent of eligible US adults ...
A Winnipeg mother with a newborn is pleading with the province to start offering RSV shots to all babies. As we navigate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback